Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 10, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in following the milestone moments of our portfolio companies.
Corporate ESG
DeltaHealth Focuses on Rural Female Teachers with Public Welfare Livestream
Recently, Qiming Venture Partners portfolio company DeltaHealth partnered with Teach For China and the HealthiHer Women's Health Alliance to focus on rural female teachers, delivering public welfare livestreams on menstrual and breast health to women teaching in rural areas of Guangdong, Yunnan, and Gansu — demonstrating a deep commitment to women's health through concrete action.
Post-event survey data showed that female teachers' satisfaction with the livestream exceeded 93%, with 98.4% of participants explicitly expressing hope for more such meaningful activities in the future. Through this initiative, DeltaHealth successfully extended advanced health management concepts and professional medical services to rural areas, contributing to improved health outcomes for rural women.
Major Partnerships
01/
BAIC Group New Energy Partners with UBTECH
Stelato Super Factory Welcomes Its First Humanoid Robot Quality Inspector
Recently, BAIC Group New Energy and Qiming Venture Partners portfolio company UBTECH (09880.HK) announced a partnership to build a world-leading humanoid robot demonstration production line for new energy vehicles, setting an industry benchmark for intelligent upgrades in high-end manufacturing. At the Stelato Super Factory — the production base for the premium all-electric flagship sedan jointly developed by BAIC Group New Energy and Huawei — UBTECH's industrial humanoid robot Walker S1 performs instrument panel material inspection tasks in the final assembly workshop, achieving 99% intelligent inspection accuracy.
As the first humanoid robot "quality inspector" at the Stelato Super Factory, Walker S1 uses a pure vision system to precisely detect the category and quantity of automotive parts, coordinating with automated inspection workflows to demonstrate a high level of intelligence. By innovatively inputting 3D reconstructed workpiece models into simulation tools to generate large volumes of synthetic data that more closely approximates real camera imaging styles, the system assists in training vision foundation models, ultimately enabling zero-shot detection based on visual prompts. To address challenges such as occluded part features, similar appearances, and closely positioned parts, Walker S1 employs tracking-based post-processing fusion technology to effectively filter and compensate for occasional false negatives and false positives across individual frames, significantly improving the reliability of inspection results.
02/
Shengshu Technology Reaches Strategic Partnership with Lenovo Capital and Incubator Group
Recently, Qiming Venture Partners portfolio company Shengshu Technology formally reached a strategic partnership with Lenovo Capital and Incubator Group. Shengshu Technology's AI video creation platform Vidu has been fully integrated into Lenovo Capital and Incubator Group's PC and smart hardware ecosystem. This marks not only a further step toward ecosystem-level collaboration between AI video foundation models and computer hardware, but also sets a new benchmark for efficient, cutting-edge AI video creation experiences.
The core of this partnership lies in combining Vidu's AI video generation capabilities with the high-performance hardware advantages of Lenovo Capital and Incubator Group's PCs, optimizing the overall AI-PC video creation workflow. Lenovo Capital and Incubator Group users will be able to generate higher-quality video content using Vidu within a more complete ecosystem. This integration allows creators to enjoy premium AI video creation experiences on lightweight devices, empowering content production upgrades across film and television, advertising, gaming, education, and other industries.
03/
Infinigence AI Reaches Strategic Partnership with Zhejiang Computing Power Technology
At the "Cloud Intelligence Convergence, Building a New AI Industry Future — Artificial Intelligence and Controllable Cloud Computing Industry Ecosystem Conference," the Hangzhou Computing Power Resource Scheduling Service Platform was officially launched. The platform is led, built, and operated by Zhejiang Computing Power Technology, with Qiming Venture Partners portfolio company Infinigence AI providing core technology and platform R&D support. It aims to achieve efficient utilization and collaborative sharing of computing power resources through intelligent scheduling and optimized allocation, effectively addressing current challenges such as uneven distribution and low utilization rates of computing resources, and providing a solid computing foundation for the development of artificial intelligence, big data, and cloud computing industries.
As the core technology support team for the Hangzhou Computing Power Resource Scheduling Service Platform, Infinigence AI and Zhejiang Computing Power Technology signed a strategic cooperation agreement. Both parties will fully leverage their respective advantages in computing infrastructure, software-hardware joint optimization, and heterogeneous computing resource integration and scheduling to jointly promote efficient utilization and collaborative sharing of computing resources. This cooperation is committed to breakthrough technical objectives including high-quality interconnection of heterogeneous computing power and operations management of 10,000-card clusters, working together to build the Hangzhou Computing Power Resource Scheduling Service Platform to achieve unified access, scheduling, and utilization of computing power.
04/
Cix Technology Signs Cooperation Agreement with Xidian Hangzhou Institute
To Co-Build Joint Innovation Center
At the "Wisdom Converges on the Qiantang, New Quality Sets Sail" conference on integrated high-quality development of education, science, and talent, hosted by the Hangzhou Institute of Xidian University (hereinafter "Xidian Hangzhou Institute"), Qiming Venture Partners portfolio company Cix Technology formally signed a cooperation agreement with Xidian Hangzhou Institute. Both parties will co-build a joint innovation center, focusing on frontier chip technology R&D and industrial ecosystem development.
According to the cooperation agreement, the joint innovation center will rely on Xidian Hangzhou Institute's research advantages and Cix Technology's technology and industrial resources, focusing on three areas: core technology R&D, industrial ecosystem development, and emerging industry incubation. This university-enterprise collaboration marks an important milestone for Cix Technology in practicing its "industry-academia-research-application" integration strategy.
05/
Shangyue Reaches Partnership with Haiqin Technology
To Jointly Advance Enterprise Procurement Digital Transformation
Recently, Qiming Venture Partners portfolio company Shangyue formally signed a partnership agreement with Haiqin Technology, a leading Chinese smart device solutions provider. Leveraging its extensive experience and technological advantages in procurement digitization, Shangyue will build a customized efficient sourcing management system for Haiqin Technology, helping optimize procurement processes, improve supply chain management efficiency, and jointly advance enterprise procurement digital transformation.
Haiqin Technology's main business currently focuses on the design, R&D, manufacturing, and sales of LCD display main control board cards, smart commercial display systems, and smart devices for interactive control and device interconnection. Its products have been widely applied in home appliances, education, government and enterprise services, and smart agriculture. This partnership with Shangyue represents a significant move by Haiqin Technology to actively embrace digital transformation and enhance its core competitiveness.
06/
Shanghai Jiao Tong University and Cix Technology Jointly Release
Protein Design Large Model Enabling "Directed Evolution"
Recently, the "Protein Function Prediction Venus Series Model Release and Industry Cooperation Summit," co-hosted by Shanghai Jiao Tong University and Qiming Venture Partners portfolio company Cix Technology, was successfully held. Hong Liang, distinguished professor at Shanghai Jiao Tong University and chief scientist at Cix Technology, released the protein design large model Venus, whose core capability is enabling "directed evolution" of protein functions. Multiple products designed by the model have already entered industrial application.
Compared with traditional methods relying on experience and high-throughput experiments, the large model Venus can complete protein sequence-to-function prediction, achieving a shift from "finding a needle in a haystack" to precise design. To enhance a specific function of a target protein, users need only provide the protein's sequence information, and Venus can rapidly generate a batch of protein sequence modification schemes, which are then combined with experimental validation to identify the optimal modification plan.
Hong Liang stated: "Data is the foundation of large models. We have established a dataset containing tens of billions of protein sequences, covering protein sequence information from conventional surface organisms to extreme-environment microorganisms, among which hundreds of millions of sequences have functional labels."
Based on this massive dataset of functionally unknown proteins, precisely identifying proteins that meet demanding application requirements and possess unconventional functions is another core capability of Venus, with the potential to unlock applications for these proteins in biotechnology, pharmaceutical R&D, and industrial production.
07/
CanSino Biologics and Grand Life Sciences
Sign Exclusive Commercialization Agreement for Adsorbed Tetanus Vaccine
Recently, Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK) and Grand Life Sciences jointly announced an exclusive commercialization agreement for the adsorbed tetanus vaccine.
Under the agreement, CanSino Biologics will authorize Grand Life Sciences to provide exclusive promotion services for its adsorbed tetanus vaccine product in Greater China upon approval, further expanding vaccine accessibility.
CanSino Biologics will receive an upfront payment, milestone payments upon product approval and upon exceeding specified revenue thresholds, totaling up to RMB 100 million over ten years from the date of signing; it will also pay promotion service fees based on promotional sales.
08/
Merck Group Senior Delegation Visits Abbisko Pharma
Further Strengthening Partnership
Recently, Hong Zhou, Merck Group Executive Vice President and Head of China and International Markets, led the Merck China and International Markets management team to visit Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) at its Shanghai R&D center. The two sides engaged in in-depth discussions on innovative drug R&D, clinical trial collaboration, and future strategic planning. This visit further consolidated the partnership and laid a solid foundation for future synergistic development.
Dr. Hongping Yu, Co-founder and Chief Scientific Officer of Abbisko Pharma, provided a detailed overview of Abbisko's pipeline progress, with particular emphasis on the latest developments and future plans for the collaborative project pimitespib. Zhou expressed recognition of this progress and high expectations for pimitespib's subsequent development. Additionally, the Merck team fully affirmed Abbisko Pharma's outstanding performance in R&D capabilities and clinical advancement efficiency.
09/
Abbisko Pharma and Ali Reach
Combination Therapy Clinical Research Cooperation Agreement
Recently, Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) announced a partnership with Ali to conduct clinical research on the combination of its investigational oral small-molecule PD-L1 inhibitor ABSK043 with Ali's KRAS G12C inhibitor glecirasib tablets for the treatment of KRAS G12C-mutated non-small cell lung cancer.
Previously, ABSK043 was also combined with Ali's self-developed furmonertinib mesylate tablets for the treatment of advanced non-small cell lung cancer. The latest Phase 1 study results of ABSK043 in patients with advanced solid tumors demonstrated favorable safety and anti-tumor activity, with higher response rates in the PD-L1 high-expression group, EGFR-mutated group, and KRAS-mutated group.
10/
MedSci Health Reaches Strategic Partnership with
China Biopharmaceutical Industry Innovation and Transformation Alliance
Recently, Qiming Venture Partners portfolio company MedSci Health (02415.HK) and the China Biopharmaceutical Industry Innovation and Transformation Alliance (CBIITA) held a strategic partnership signing ceremony, officially launching the CBIITA-MedSci Clinical Research Innovation Empowerment Program. The two sides will collaborate closely on research training, basic research, clinical research, clinical translation, evidence dissemination, and industrial application, accelerating the upgrade of clinical research value.
Shuai Wang, Co-CEO of MedSci Health, provided a detailed introduction to the CBIITA-MedSci Clinical Research Innovation Empowerment Program. Through "dual-engine drive," the two sides will cooperate on expert-led scientific innovation, disciplinary development, and research talent cultivation, jointly helping break down technical barriers and accelerate clinical translation. CBIITA will provide full-chain support in industrial resources, industry-academia-research collaboration integration, and specialized incubation and ecosystem building; MedSci Health will provide deep empowerment in physician professional development, digital clinical research, and digital medical communication.
11/
Frontage Pharma Subsidiary and ASG Reach Strategic Partnership on
Novel Dry Powder Inhalation Formulation Drug Development and Manufacturing
Recently, Qiming Venture Partners portfolio company Frontage Pharma subsidiary Frontage Pharmaceutical and ASG (Asia Standard Global) jointly announced that the two sides have established a solid cooperation foundation on the ASG-β-1 dry powder inhalation capsule development and manufacturing project. ASG will continue to entrust Frontage Pharmaceutical with the manufacturing and R&D support for multiple dry powder inhalation capsule projects.
Frontage Pharmaceutical can meet precise particle size control requirements through jet milling and spray drying; its high-shear mixing equipment ensures uniformity for low-dose products; and its Fine Particle Fraction (FPF) reaches 50%, with lung deposition efficiency at an industry-leading level — laying the groundwork for high bioavailability.
12/
Zhidging Medical and Xianwei Medical Sign Strategic Partnership
Recently, Qiming Venture Partners portfolio company Zhidging Medical signed a strategic cooperation agreement with Xianwei Medical. This partnership marks an important step forward for Zhidging Medical in advancing comprehensive dry eye diagnosis and treatment solutions, as well as future intelligent ophthalmic care.
Zhidging Medical will be responsible for market expansion and sales of Xianwei Medical's Aimus™ LipiFlow thermal pulsation system in public hospitals, helping to promote the clinical application of advanced dry eye treatments. The collaboration will leverage Zhidging Medical's market channels and brand influence alongside Xianwei Medical's innovative technology to jointly drive standardization and intelligentization of dry eye care, further improving patient treatment experiences.
R&D Progress
01/
Gan & Lee Pharmaceuticals Hosts GZR4-T2D-302 Clinical Trial Investigator Meeting
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) hosted the GZR4-T2D-302 clinical trial investigator meeting in Beijing. The meeting focused on the trial protocol and execution strategy for the GZR4-T2D-302 project, attracting over 200 clinical investigators from more than 80 hospitals across China in a hybrid online-offline format.
Dr. Gan Zhongru, Chairman of Gan & Lee Pharmaceuticals, delivered the opening remarks, reviewing the company's R&D journey in diabetes treatment — from breakthroughs in insulin analogs to its current multi-pipeline innovative drug portfolio. Dr. Gan noted that GZR4 injection, an ultra-long-acting insulin analog developed independently by Gan & Lee, features unique molecular design and preclinical data demonstrating differentiated advantages, with the potential to become the first domestically developed once-weekly insulin formulation. He stated that the meeting aimed to pool clinical experts' wisdom, drive efficient Phase 3 trial execution, accelerate the new drug's path to market, and bring new hope to diabetes patients.
02/
Ark Biosciences Announces Completion of Phase 3 Clinical Trial for ADHD Drug Aizhida™
Recently, Qiming Venture Partners portfolio company Ark Biosciences announced the successful completion of its Phase 3 clinical study for Aizhida™ (AK0901), a new drug for treating attention deficit hyperactivity disorder (ADHD) in children and adults. This milestone marks solid progress in Ark Biosciences' drug development for pediatric psychiatric disorders and promises to provide new treatment options and improved experiences for ADHD patients in China.
Aizhida™ (AK0901) is the world's first and currently only combination formulation containing immediate-release dexmethylphenidate (d-MPH) and prodrug serdexmethylphenidate (SDX). It works by inhibiting reuptake of dopamine and norepinephrine in the brain, increasing their concentration in synapses and thereby improving neurotransmitter transmission efficiency to alleviate ADHD symptoms. Aizhida™ is a best-in-class innovative therapeutic for ADHD patients. Approved in the United States in March 2021, it was the first new-generation methylphenidate drug approved by the FDA in nearly 20 years, offering clear advantages in safety profile and mechanism of action.
03/
Dingtail Pharmaceutical Research Group Supports YB-01 in Obtaining Clinical Trial Approval from CDE
Recently, Qiming Venture Partners portfolio company Dingtail Pharmaceutical Research Group's partner Yuanben Biotech announced that its independently developed innovative biopharmaceutical, YB-01 for injection, received clinical trial approval from the Center for Drug Evaluation, NMPA (CDE) (application number CXSL2400895). Dingtail Pharmaceutical Research Group provided comprehensive support for YB-01's non-clinical studies through its leading technical expertise, extensive project experience, and quality resources.
Dingtail Pharmaceutical Research Group completed the YB-01 project's non-clinical pharmacokinetics and safety evaluation studies (covering repeated-dose toxicity, immunogenicity and immunotoxicity, and safety pharmacology studies) in a compliant, high-quality, and efficient manner, and provided SEND data conversion services. This rapidly supported the product's IND applications in both China and the United States, significantly accelerating YB-01's drug development process.
Product Launches
MedGenome Supports Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan in Securing Second NMPA Approval
Recently, Qiming Venture Partners portfolio company MedGenome's partner Kelun-Biotech announced that its independently developed sacituzumab tirumotecan (sac-TMT, brand name: Jiatailai®) — the world's first TROP2-targeted antibody-drug conjugate (ADC) — received its second approval from the National Medical Products Administration (NMPA). The new indication covers adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation-positive status who have progressed after treatment with EGFR tyrosine kinase inhibitors (TKI) and platinum-containing chemotherapy.
MedGenome provided comprehensive technical support throughout Jiatailai®'s clinical development. Leveraging its full-platform translational medicine solutions, MedGenome delivered high-quality TROP2 IHC testing support for the drug's clinical studies and regulatory filing, facilitating its successful approval. With internationally standardized quality systems and globally leading detection technology, MedGenome ensured the stability, reproducibility, and clinical applicability of TROP2 IHC testing, providing robust technical assurance for Jiatailai®'s smooth market launch.
Technology Strength
01/
Roborock Debuts at AWE 2025
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) unveiled its full range of new products at the 2025 Appliance & Electronics World Expo (AWE).
The Roborock G30 Space Exploration Edition redefines the next generation of home robots, featuring the industry's first 5-axis foldable biomimetic robotic arm — a leap from two-dimensional floor cleaning to three-dimensional spatial control. The Roborock A30 Pro Steam comes with an upgraded Zero-Sensation Cleaning System Pro and introduces the industry's first dual steam-and-hot-water floor washing function, delivering true zero residue, zero tangles, zero blind spots, and zero burden. The Roborock Z1S Pro features a full-screen futuristic design and innovative drying technology that reshapes the laundry experience. The Roborock H50 Ultra ensures 100 days of dust-free operation, with its pioneering five-in-one all-in-one station and Zero-Sensation Cleaning System Pro freeing users from manual intervention.
In 2024, Roborock ranked first globally in both sales volume and revenue for robot vacuums. Its products are now available in over 230 countries and regions, used by more than 17 million households worldwide, with over 1.7 million daily active users on its app globally.
02/
Hesai Technology Appears at International Top-Tier Laser Safety Conference
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) appeared at the International Laser Safety Conference (ILSC), delivering three presentations and publishing three academic papers. Hesai was the only Chinese company and the only lidar company to publicly publish papers at the conference, demonstrating its outstanding leadership in laser safety applications, standards development, and industry innovation.
Hesai noted that when assessing laser safety for electric vehicles, the potential cumulative effects of radiation from multiple laser products must be considered. This is because electric vehicles equipped with multiple laser components may produce multiple laser beams during operation, and these beams could overlap in space. Care must be taken to prevent the combined laser radiation from exceeding safety thresholds, thereby avoiding potential harm to eyes and skin. Hesai also recommended that new industry standards and specifications be developed for safety assessment of automotive lidar, clearly defining the responsibilities of OEMs, lidar manufacturers, and users regarding laser safety.
03/
StepFun Open-Sources Step-Video-TI2V Image-to-Video Model
Recently, Qiming Venture Partners portfolio company StepFun announced the open-sourcing of its image-to-video model, Step-Video-TI2V. Built on the 30B-parameter Step-Video-T2V, this model supports generation of 102-frame, 5-second videos at 540P resolution. Its two core features are controllable motion magnitude and controllable camera movement, along with inherent special effects generation capabilities.
Compared to currently available open-source image-to-video models, Step-Video-TI2V not only raises the ceiling for research in this field through its parameter scale, but its controllable motion magnitude capability also balances dynamism and stability in generated results, offering creators greater flexibility.
04/
Yunji Technology Participates in AWE China
At the 2025 Appliance & Electronics World Expo (AWE), Qiming Venture Partners portfolio company Yunji Technology unveiled its groundbreaking composite polymorphic robot, UP, at its booth. As one of the first composite polymorphic robot products launched globally, UP demonstrated technology-driven embodied artificial intelligence innovations at the exhibition.
Unlike first-generation all-in-one machines, Yunji's composite polymorphic robot UP features three distinctive advantages: tool use, task comprehension and reasoning, and swarm collaboration. Through its "1+N+AIoT" model, it enables all-hours, multi-scenario, multi-function, multi-task operation, achieving end-to-end closed-loop AI agent services.
05/
TINGSN Technology Assists Nanjing Drum Tower Hospital Team in Complex Cardiac Device Replacement Surgery
Recently, a team led by Professor Xu Wei at Nanjing Drum Tower Hospital successfully completed a pacemaker removal and cardiac resynchronization defibrillator implantation procedure guided by Qiming Venture Partners portfolio company TINGSN Technology's intracardiac echocardiography (ICE) product, setting a new benchmark for complex cardiac device replacement surgeries.
Using an ICE catheter with a diameter of just 3.3 millimeters, the medical team could assess the integrity of existing leads in real time (such as fractures or insulation damage) while observing contact between leads and myocardial tissue, valves, and blood vessels, ensuring surgical safety.
06/
Prismlab Showcases High-Precision Micro-Nano 3D Printer and SLS Nylon 3D Printer at TCT Asia 2025
Recently, Qiming Venture Partners portfolio company Prismlab showcased its high-precision micro-nano 3D printer and SLS nylon 3D printer at TCT Asia 2025.
The Prismlab high-precision micro-nano 3D printer was a major highlight of the exhibition. Based on self-developed sub-pixel micro-scanning technology (SMS), it uses area-array exposure without complex stitching, completely eliminating stitching errors, with printing precision reaching 2 microns. This ultra-high-precision capability gives it unmatched advantages in precision manufacturing, easily handling complex structures and precision dimensions that traditional processes struggle to achieve.
The Prismlab SLS nylon 3D printer achieves rapid printing through optimized overall structural design and is compatible with multiple powder materials including PA12, PA11, and PA6. At the exhibition, the printer demonstrated its wide industrial applications, including automotive parts, aerospace components, and precision molds. The equipment not only meets the efficiency demands of large-scale production but also effectively reduces manufacturing costs and enhances enterprise competitiveness.
07/
JST Medical Appears at AAOS Annual Meeting
At the American Academy of Orthopaedic Surgeons (AAOS) annual meeting, Qiming Venture Partners portfolio company JST Medical showcased its innovative products, highlighting recent advances across hip and knee solutions, regenerative repair, artificial intelligence, and sports medicine — from standard products to breakthrough technologies, all demonstrating safety, efficacy, and refinement.
JST Medical consistently practices its corporate value proposition of "focusing on staged joint treatment to enhance quality of life." Since launching its international business, its products have been sold in 49 countries and regions, earning high praise from physicians and patients.
Corporate Honors
Ten Qiming Venture Partners Portfolio Companies Win BIOCHINA Awards
At BIOCHINA 2025 (the 10th edition), the BIOCHINA Awards results were announced. The awards aim to recognize innovative forces in the biopharmaceutical industry.
Qiming Venture Partners portfolio companies MediLink Therapeutics, LaNova Medicines, Hope Medicine, and Laekna Biopharma were named to the 2024 Innovative Breakthrough Companies list. ZhenGe Biologics, Inscinstech, Crown Bioscience, BioLink, MedGenome, and Zhongxi Biotech were named to the 2024 Supplier list.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 09, 2025
Qiming Stars | Ten Qiming Venture Partners Portfolio Companies Win BIOCHINA Awards
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.